Zhou Zhiwei, Farhan Mohd, Xing Xingan, Zhou Wenshu, Lin Ruohong, Zeng Shan, Li Mengfang, Zheng Wenhua
Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
MOE Frontier Science Center for Precision Oncology, University of Macau, Macau, China.
Int J Biol Sci. 2025 Jan 1;21(1):75-94. doi: 10.7150/ijbs.97341. eCollection 2025.
Cancer radical surgery is the primary treatment for melanoma, but almost all malignant melanoma patients get recurrence and metastasis after surgery and are eventually dead. This clinical dilemma appeals to better drugs for post-surgery therapy. Artemisinin is a safe and effective antimalarial drug used in the clinic for decades. However, no information is available regarding the effect of Artemisinins on melanoma recurrence and metastasis after tumor excision. In the present study, we established a post-surgery tumor model on balb/c nude mice, and we found that subclinical dosages of Artemisinin significantly blocked recurrence, metastasis, and extended survival time of mice after tumor excision. Similar results were obtained in the experiments with B16 and A375 cell lines. Further experiments confirmed that Artemisinin inhibits melanoma and after radical surgery by the c-KIT/PI3K/AKT signaling pathway. Our findings support the therapeutic potential of Artemisinin in malignant melanoma after surgery.
癌症根治性手术是黑色素瘤的主要治疗方法，但几乎所有恶性黑色素瘤患者术后都会复发和转移，最终死亡。这种临床困境促使人们寻求更好的术后治疗药物。青蒿素是一种安全有效的抗疟药物，已在临床上使用了数十年。然而，关于青蒿素对肿瘤切除后黑色素瘤复发和转移的影响尚无相关信息。在本研究中，我们在balb/c裸鼠上建立了术后肿瘤模型，发现亚临床剂量的青蒿素能显著阻断肿瘤切除后小鼠的复发、转移，并延长其生存时间。在B16和A375细胞系实验中也得到了类似结果。进一步实验证实，青蒿素通过c-KIT/PI3K/AKT信号通路抑制黑色素瘤根治术后的复发和转移。我们的研究结果支持了青蒿素在恶性黑色素瘤术后的治疗潜力。
